Table 2 Correlation of overall and progression-free survival (Kaplan–Meier estimates, log-rank tests and Cox regression) according to stromal or cytoplasmic SPARC expression in the total study population, in the primary tumour and metastatic tissue subgroups and in the gemcitabine-based and fluoropyrimidine- based treatment subgroups

From: Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials

 

n

%

OS (months)

P (log-rank)

HR

95% CI

PFS (months)

P (log-rank)

HR

95% CI

Stromal SPARC

 Total

          

 High

90

67

9.1

0.316

0.823

0.562–1.205

7.0

0.314

1.254

0.805–1.953

 Low

44

34

7.6

   

5.9

   

 Primary tumour

          

 High

46

72

10.8

0.857

0.948

0.528–1.701

8.6

0.792

1.099

0.543–2.224

 Low

18

18

8.3

   

7.4

   

 Metastasis

          

 High

44

63

7.8

0.319

0.772

0.463–1.287

6.6

0.539

1.199

0.671–2.141

 Low

26

37

6.8

   

4.1

   

Cytoplasmic SPARC

 Total

          

 Positive

74

55

7.8

0.032

1,505

1.034–2.190

6.2

0.004

1.878

1.208–2.921

 Negative

60

45

8.4

   

8.6

   

 Primary tumour

          

 Positive

36

56

7.9

0.030

1,839

1.054–3.211

6.7

0.004

2.680

1.335–5.379

 Negative

28

44

11.9

   

10.8

   

 Metastasis

          

 Positive

38

55

7.0

0.452

1,216

0.730–2.025

5.8

0.502

1.215

0.688–2.145

 Negative

32

45

7.8

   

6.6

   

Gemcitabine subgroup

 Stromal SPARC

          

 High

72

62.5

9.9

0.180

0.762

0.499–1.141

7.8

0.192

1.379

0.848–2.242

 Low

40

37.5

7.6

   

5.8

   

 Cytoplasmic SPARC

          

 Positive

60

53.6

7.3

0.012

1.693

1.114–2.560

6.2

0.002

2.158

1.319–3.531

 Negative

52

46.4

9.9

   

9.2

   

Fluopyrimidine subgroup

 Stromal SPARC

          

 High

18

81.8

7.2

0.765

1.192

0.386–3.646

4.0

0.651

0.751

0.210–2.694

 Low

4

18.2

4.0

   

2.2

   

 Cytoplasmic SPARC

          

 Positive

14

63.6

9.1

0.106

0.474

0.188–1.197

6.7

0.032

0.282

0.082–0.966

 Negative

8

36.4

4.1

   

2.2

   
  1. Abbreviations: CI=confidence interval; HR=hazard ratio; OS=(median) overall survival; PFS=(median) progression-free survival; SPARC=secreted protein acidic and rich in cysteins.
Back to article page